title: Lack of nephrotoxicity of gadodiamide in unselected hospitalized patients.
abstract: BACKGROUND
  The nephrotoxicity of gadolinium-based magnetic resonance contrast media has not been adequately studied.
  
  
  METHODS
  We evaluated the nephrotoxicity of gadolinium-based contrast media in hospitalized patients who underwent magnetic resonance imaging (MRI) as part of routine clinical care. Subjects who had a serum creatinine measurement during the 7 days before MRI and at least 1 other measurement 2 to 3 days after MRI were included. Patients who underwent noncontrasted MRI served as controls.
  
  
  RESULTS
  There were 162 subjects (mean age, 57.8 +/- 16.9 years; 91 men and 71 women) and 125 controls (mean age, 64.6 +/- 18 years; 62 men and 63 women). All contrast-enhanced MRI studies utilized gadodiamide (Omniscan; GE Healthcare, Waukesha, WI). Subjects who received gadodiamide showed no difference in the incidence of acute renal insufficiency compared with controls (increase in serum creatinine >or= 25%, 11.1% vs 12.9%, respectively; P = 0.6; increase in serum creatinine by 0.5 mg/dL, 5.6% vs 3.2%, respectively; P = 0.4). There was no significant increase in serum creatinine baseline versus 48 hours in either the subjects who received gadodiamide (0.95 +/- 0.58 vs 0.96 +/- 0.65 mg/dL; P = 0.7) or controls (0.96 +/- 0.65 vs 0.88 +/- 0.43 mg/dL; P = 0.7).
  
  
  CONCLUSIONS
  Our findings showed a lack of significant nephrotoxicity of gadodiamide in unselected hospitalized patients.
authors.affiliation: Department of Internal Medicine-Nephrology, Medical College of Wisconsin, Milwaukee, WI 53005, USA. htrivedi@mcw.ed
authors.forename: Hariprasad
authors.initials: H
authors.lastname: Trivedi
authors.forename: Lakshmi
authors.initials: L
authors.lastname: Raman
authors.forename: Heather
authors.initials: H
authors.lastname: Benjamin
authors.forename: Ruchika
authors.initials: R
authors.lastname: Batwara
mesh_terms: D058186:Acute Kidney Injury / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis*; D000581:Amidohydrolases / Q000097:blood; D003287:Contrast Media / Q000009:adverse effects*; D005260:Female; D019786:Gadolinium DTPA / Q000009:adverse effects*; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged
chemical_list: D003287:Contrast Media; C064925:gadodiamide; D000581:Amidohydrolases; C019946:creatininase; D019786:Gadolinium DTPA